Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients
NCT06176729
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
30
Enrollment
OTHER
Sponsor class
Conditions
Diffuse Large B Cell Lymphoma
Interventions
DRUG:
Polatuzumab Vedotin, Rituximab, Lenalidomide
Sponsor
Yan Zhang, MD
Collaborators
[object Object]
[object Object]
[object Object]